A few words on Skyhawk’s Phase 1c interim results – SKY-0515 in Huntington’s disease
Dr. Ignacio Muñoz-Sanjuan, Factor-H president, shares in this article his first insights on the Skyhawk’s Therapeutics announcement from January 28. There are always two sides with any important development regarding possible treatments for a devastating condition like Huntington’s Disease: one is the scientific part of it; the other is how the results of any trial […]
English 
Español 
Português do Brasil